Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno- and homografts
Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno- and homografts
复制标题
DOI：
10.1016/j.biomaterials.2012.03.015
复制
发表时间：
2012-06-01
期刊：
影响因子：
14
通讯作者：
Baaijens, Frank P. T.
中科院分区：
文献类型：
--
作者：
Dijkman, Petra E.;Driessen-Mol, Anita;Baaijens, Frank P. T.
脱细胞异种或同种异体心脏瓣膜已被用作瓣膜置换术的组织工程的起始基质，具有（预）临床有希望的结果。然而，异种移植物与免疫原性反应或疾病传播的风险相关，并且同种移植物的可用性有限。或者，可生物降解的合成材料已被用于成功地创建组织工程心脏瓣膜（TEHV）。然而，这种TEHV与大量的技术和后勤复杂性相关，并且尚未进入临床使用。在这里，脱细胞TEHV，基于可生物降解的合成材料和同源细胞，被引入作为引导组织再生的替代起始基质。TEHV的去细胞化没有改变胶原结构或组织强度，并且与其细胞填充的对应物相比有利于瓣膜性能。储存脱细胞TEHV长达18个月未改变瓣膜组织特性。当模拟经心尖瓣膜输送时，证明了用间充质干细胞重新种植脱细胞瓣膜的可行性，对重新种植的瓣膜的损伤最小。总之，体外生长的TEHV的去细胞化提供了大量可用的现成的同源支架，其适合于用自体细胞重新接种和经心尖瓣膜递送。(C)2012爱思唯尔有限公司保留所有权利。
Decellularized xenogenic or allogenic heart valves have been used as starter matrix for tissue-engineering of valve replacements with (pre-)clinical promising results. However, xenografts are associated with the risk of immunogenic reactions or disease transmission and availability of homografts is limited. Alternatively, biodegradable synthetic materials have been used to successfully create tissue-engineered heart valves (TEHV). However, such TEHV are associated with substantial technological and logistical complexity and have not yet entered clinical use. Here, decellularized TEHV, based on biodegradable synthetic materials and homologous cells, are introduced as an alternative starter matrix for guided tissue regeneration. Decellularization of TEHV did not alter the collagen structure or tissue strength and favored valve performance when compared to their cell-populated counterparts. Storage of the decellularized TEHV up to 18 months did not alter valve tissue properties. Reseeding the decellularized valves with mesenchymal stem cells was demonstrated feasible with minimal damage to the reseeded valve when trans-apical valve delivery was simulated. In conclusion, decellularization of in-vitro grown TEHV provides largely available off-the-shelf homologous scaffolds suitable for reseeding with autologous cells and trans-apical valve delivery. (C) 2012 Elsevier Ltd. All rights reserved.